Ottawa International Conference on Neuromuscular Disease and Biology 2025 (Ottawa NMD)

Back

Sustained Functional Improvement with DYNE-251 in Males with DMD Mutations Amenable to Exon 51 Skipping Enrolled in the Phase 1/2 DELIVER Trial (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.